DR. LAL PATHLABS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,600 INR | +1.69% |
|
+5.04% | +0.80% |
| May. 14 | Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 | MT |
| May. 10 | Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024 |
Evolution of the average Target Price on Dr. Lal PathLabs Limited
Price target over the last 5 years
History of analyst recommendation changes
becc6c019c5f57f400b.UmEbgh0fQtIyufqaTeyuY1qGAg0Wr9FAFfRM__bx6_8.PRhK2mgse-RUwMjcD5rgUBbqVExmzKsOQJENp7SZiYcfVHXpbFU7vAv4kQ~7e036e694b65118e6ef71f6efd94bbcc
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
2,556
INR
Average target price
2,489
INR
Spread / Average Target
-2.64%
High Price Target
2,900
INR
Spread / Highest target
+13.44%
Low Price Target
1,670
INR
Spread / Lowest Target
-34.68%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Dr. Lal PathLabs Limited
| Nomura | |
| Jefferies & Co. |
Trading Rating
Investor Rating
ESG Refinitiv
B-
EPS Revisions
- Stock Market
- Equities
- LALPATHLAB Stock
- Consensus Dr. Lal PathLabs Limited